Australia NHMRC Backs Puberty Blockers in Some Cases

Australia's National Health and Medical Research Council (NHMRC) has said puberty blockers may be considered for some transgender and gender-diverse young people under 18, in interim advice published on Monday, 16 November 2026.
The advice, titled "Advice on the use of puberty suppressants in the care of trans and gender diverse people aged under 18", is Australia's first nationally endorsed clinical advice on puberty blockers. It gives a conditional recommendation, meaning the treatment may be considered in carefully selected cases, subject to a series of conditions.
What the advice says
Under the advice, puberty suppressants, also known as gonadotropin-releasing hormone (GnRH) agonists, may be considered for a young person who has begun puberty, has gender incongruence, and has been assessed as suitable for treatment. Any decision must be made jointly by the young person, their parents or carers, and their clinicians, with treatment decisions taken on an individual basis.
The NHMRC judged the overall evidence on the benefits and risks to be of low certainty, based mainly on 15 short-term, non-randomised observational studies. It said the treatment may improve psychosocial functioning and might reduce suicidal behaviours, but found no eligible evidence on its effects on fertility or long-term bone health. Reporting of the advice also noted limited evidence on fertility and that the medication could affect bone health in the short to medium term.
Why the review was commissioned
Federal Health Minister Mark Butler asked the NHMRC in January 2025 to develop national guidelines for the care of trans and gender-diverse young people, after Queensland and the Northern Territory restricted access to puberty blockers in their public hospitals. The new advice replaces guidelines first published in 2018 that were not endorsed by the NHMRC.
Mr Butler said on Monday that the NHMRC advice suggested puberty blockers could be used in certain circumstances and subject to a range of conditions, including shared decision-making and consent. He urged states and territories to consider the advice. The guidance is not legally binding, and each state and territory decides its own policy.
States reject the advice
Queensland and the Northern Territory immediately rejected the interim advice and said they would keep their restrictions in place. Queensland banned puberty blockers in public hospitals in January 2025, and reporting of the decision said the state's restrictions had been extended until 2031, when the UK's PATHWAYS clinical trial is due to conclude.
NHMRC acting chief executive Prue Torrance said the guidance would help young people and their families make informed decisions about their care. The interim advice is open for public consultation until 18 January 2027, and the full national guidelines on gender-affirming care, including hormones, are expected in 2028.